BI 207127 NA

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyHepatitis C, Chronic

Phase 1

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

CompletedNCT01605461

Boehringer IngelheimHealthy

Start: 2012-05-31End: 2012-06-30Updated: 2016-03-21

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

CompletedNCT02176525

Boehringer IngelheimHepatitis C, Chronic

Start: 2007-12-31Updated: 2016-06-06

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

TerminatedNCT02182401

Boehringer IngelheimHealthy

Start: 2009-07-31Updated: 2014-07-18

Phase 2

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

CompletedNCT01528735

Boehringer IngelheimHepatitis C, Chronic

Start: 2012-02-29End: 2013-08-31Updated: 2016-04-13

Related Papers

Open‐label phase 2 study of faldaprevir, deleobuvir and ribavirin in Japanese treatment‐naive patients with chronic hepatitis C virus genotype 1 infection

Hepatology Research2015-05-20